Stem Cell and Biomaterials

Stem Cell Culture and Bioprocessing

Getting cell therapy product onto the market as quickly as possible still remains a key driver within the improvement of recombinant therapeutic proteins. Any such advance in bioprocessing is of specific interest to the industry if it significantly shortens the event timeline or improves the end product. within the monoclonal antibody (MAb) area, platform procedures have allowed companies to manage on specific mammalian cell lines, transfection approaches, process conditions and additionally downstream processing to shorten the development timeline.